Genomic analysis of Brevibacillus thermoruber 423 reveals its biotechnological and industrial potential
- 511 Downloads
Brevibacillus thermoruber 423 is a Gram-positive, motile, red-pigmented, spore-forming, aerobic, and thermophilic bacterium that is known to produce high levels of exopolysaccharide (EPS) with many potential uses in food, feed, cosmetics, and pharmaceutical and chemical industries. This bacterium not only is among the limited number of reported thermophilic EPS producers but also exceeds other thermophilic producers in light of the high level of polymer synthesis. By a systems-based approach, whole-genome analysis of this bacterium was performed to gain more insight about the biological mechanisms and whole-genome organization of thermophilic EPS producers and hence to develop rational strategies for the genetic and metabolic optimization of EPS production. Also with this study, the first genome analysis was performed on a thermophilic Brevibacillus species. Essential genes associated with EPS biosynthesis were detected by genome annotation, and together with experimental evidences, a hypothetical mechanism for EPS biosynthesis was generated. B. thermoruber 423 was found to have many potential applications in biotechnology and industry because of its capacity to utilize xylose and to produce EPS, isoprenoids, ethanol/butanol, lipases, proteases, cellulase, and glucoamylase enzymes as well as its resistance to arsenic.
KeywordsBrevibacillus thermoruber Thermophiles Genome Next-generation sequencing Exopolysaccharide
This research has been conducted under infrastructure built via financial support by the Scientific and Technological Research Council of Turkey (TUBITAK) through grants 111 T016 and 110 M613, and by Marmara University through project FEN-C-DRP-110913-0380.
Conflict of interest
The authors declare that they have no competing interests.
- Baek DH, Kwon SJ, Hong SP, Kwak MS, Lee MH, Song JJ, Lee SG, Yoon KH, Sung MH (2003) Characterization of a thermostable D-stereospecific alanine amidase from Brevibacillus borstelensis BCS-1. Appl Environ Microbiol 69:980–986. doi:10.1128/AEM. 69.2.980-986.2003 CrossRefPubMedCentralPubMedGoogle Scholar
- Caipang CMA, Verjan N, Ooi EL, Kondo H, Hirono I, Aoki T, Kiyono H, Yuki Y (2008) Enhanced survival of shrimp, Penaeus (Marsupenaeus) japoni from white spot syndrome disease after oral administration of recombinant VP28 expressed in Brevibacillus brevis. Fish Shellfish Immunol 25:315–320. doi:10.1016/j.fsi.2008.04.012 CrossRefPubMedGoogle Scholar
- Hamza HM, Ali SM, Hassan HG (2006) Partial purification of gelatinase enzyme from local isolate of Brevibacillus laterosporus. Iraqi National J Chem 23:437–442Google Scholar
- Rehm BH (2009) Microbial production of biopolymers and polymer precursors: applications and perspectives. Horizon Scientific Press, Wymondham, Norfolk, UKGoogle Scholar
- Sharma G, Prakash D, Gupta C, Prakash D, Sharma G (2014) Phytochemicals of nutraceutical importance: do they defend against diseases? In: Prakash D, Sharma G (eds) Phytochemicals of nutraceutical importance. CABI, Boston, MA, pp 1–23Google Scholar
- Tokunaga M, Mizukami M, Yamasaki K, Tokunaga H, Onishi H, Hanagata H, Ishibasi M, Miyauchi A, Tsumoto K, Arakawa T (2013) Secretory production of single-chain antibody (scFv) in Brevibacillus choshinensis using novel fusion partner. Appl Microbiol Biotechnol 97:8569–8580. doi:10.1007/s00253-013-4695-2 CrossRefPubMedGoogle Scholar
- Yuki Y, Hara‐Yakoyama C, Guadiz AA, Udaka S, Kiyono H, Chatterjee S (2005) Production of a recombinant cholera toxin B subunit‐insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes. Biotechnol Bioeng 92:803–809. doi:10.1002/bit.20654 CrossRefPubMedGoogle Scholar